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Summary
 
Human CD8
 
1
 
 memory- and effector-type T cells are poorly defined. We show here that, next
to a naive compartment, two discrete primed subpopulations can be found within the circulat-
ing human CD8
 
1
 
 T cell subset. First, CD45RA
 
2
 
CD45R0
 
1
 
 cells are reminiscent of memory-
type T cells in that they express elevated levels of CD95 (Fas) and the integrin family members
CD11a, CD18, CD29, CD49d, and CD49e, compared to naive CD8
 
1
 
 T cells, and are able to
 
secrete not only interleukin (IL) 2 but also interferon 
 
g
 
, tumor necrosis factor 
 
a
 
, and IL-4. This
subset does not exert cytolytic activity without prior in vitro stimulation but does contain vi-
rus-specific cytotoxic T lymphocyte (CTL) precursors. A second primed population is charac-
terized by CD45RA expression with concomitant absence of expression of the costimulatory
molecules CD27 and CD28. The CD8
 
1
 
CD45RA
 
1
 
CD27
 
2
 
 population contains T cells ex-
pressing high levels of CD11a, CD11b, CD18, and CD49d, whereas CD62L (L-selectin) is not
expressed. These T cells do not secrete IL-2 or -4 but can produce IFN-
 
g
 
 and TNF-
 
a
 
. In ac-
cordance with this finding, cells contained within this subpopulation depend for proliferation
 
on exogenous growth factors such as IL-2 and -15. Interestingly, CD8
 
1
 
CD45RA
 
1
 
CD27
 
2
 
 
 
cells
parallel effector CTLs, as they abundantly express Fas-ligand mRNA, contain perforin and
granzyme B, and have high cytolytic activity without in vitro prestimulation. Based on both
phenotypic and functional properties, we conclude that memory- and effector-type T cells can
be separated as distinct entities within the human CD8
 
1
 
 T cell subset.
 
R
 
ecognition of antigen by the immune system evokes a
coordinate number of changes in lymphocytes and
 
lymphocyte subsets that allow the system (
 
a
 
) to eliminate or
neutralize potential harmful agents and (
 
b
 
) to respond more
rapidly and appropriately after renewed antigen encounter,
a process referred to as immunological memory. Within
the T cell compartment, unprimed (or naive) T cells (i.e.,
cells which have not yet encountered antigen), effector T
cells (i.e., cells with specialized functions such as cytolysis),
and memory T cells can be discerned. Functionally, mem-
ory T cells have a number of characteristics that distinguish
them from unprimed cells. Not only do they respond effi-
ciently to recall antigens, but, compared to naive cells,
memory T cells also have less stringent requirements for ac-
tivation and have the potential to secrete a more extensive
set of cytokines (1–4). In addition, memory and naive T
cells differ in the expression of several cell surface antigens
(5, 6), although it is questioned whether these markers can
be looked upon as true memory markers or if they reflect
cellular activation (7, 8).
Recent studies by Zimmermann et al. (9) have docu-
mented phenotypic distinctions between naive, effector,
and memory CD8
 
1
 
 T cells in a murine model of lympho-
cytic choriomeningitis virus infection and an adoptive
transfer system with CD8
 
1
 
 T cells from TCR transgenic
mice. Their data confirmed previous reports (10–14) by
demonstrating that compared to naive T cells CTL effec-
tors have strongly downregulated the lymph node homing
receptor CD62L (L-selectin) while expression of CD44,
CD11a/CD18, CD11b, and CD49d is enhanced. In con-
trast to effector T cells, memory T cells are heterogenous
with respect to CD62L expression, have no CD11b on
their surface, and have an intermediate CD49d expression.
Finally, CD45 isoform expression could not be used as a
reliable marker for memory-type T cells (9).
In contrast to the murine T cell subsets, description of
human CD8
 
1
 
 naive, effector, and memory cells is still
rather fragmentary. Cytolytic function of CD8
 
1
 
 cells has
been linked to cells with a CD28
 
2
 
, a CD11b
 
1
 
, and/or a
CD57
 
1
 
 phenotype (11, 15, 16). Moreover, memory-type
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CD8
 
1 
 
CD45RA
 
2
 
CD45R0
 
1
 
 T cell subsets that contain en-
hanced frequencies of antigen-reactive precursor cells (17),
have low stringent activation requirements, and have an
ability to secrete, apart from IL-2, IFN-
 
g
 
 and TNF-
 
a
 
 (18),
have been previously described. However, discrimination
between naive and memory cells, based solely on CD45
isoform expression, has been proven unreliable, since the
CD45RA
 
1
 
 population contains cells that share a number of
phenotypic features with primed cells, such as low CD62L
(19) and high CD11a/CD18 (20) expression. Moreover,
part of the CD45RA
 
1
 
 cells have downregulated CD27
(21), a feature considered to result from persistent antigenic
stimulation in vivo (22, 23).
In this study we used simultaneous staining with CD45RA
and CD27 mAbs to separate functionally distinct subpopu-
lations of human CD8
 
1
 
 T cells. Our observations demon-
strate that, within the human CD8
 
1
 
 compartment, in accor-
dance with data obtained in experimental animal models,
naive, memory- and effector-type cells can be discriminated
with coherent phenotypic and functional properties. This type
of CD8
 
1
 
 T cell subset analysis could prove useful in moni-
toring the immune system in several clinical situations.
 
Materials and Methods
 
Reagents.
 
The mAbs CLB-T11.1/1, CLB-T11.2/1, CLB-
HIK27 (all CD2), CLB-CD3/3 CLB-CD3/4.1, CLB-CD4/1,
CLB-CD8/1, CLB-CD14/1, CLB-FcR gran1 (CD16), CLB-
CD19/1, CLB-CD27/1, CLB-CD28, CLB-LFA-1/1 (CD18),
CLB-CD49d (VLA-4), and CLB-CD49e (VLA-5), and FITC-
conjugated goat anti–mouse Ig, were all produced at the Central
Laboratory of the Netherlands Red Cross Blood Transfusion
Service (CLB; Amsterdam, The Netherlands). CD95 mAb was
provided by Dr. Yonehara (Pharmaceutical Basic Research, Tokyo,
Japan) and CD58 mAb (TS2/9) was a gift from Dr. T.A. Springer
(Center for Blood Research, Boston, MA). CD11b (OKM-1)
mAb was purchased from Ortho Diagnostic Systems (Beerse,
Belgium). FITC-conjugated–CD62L (Leu-8), –CD57, –CD16,
–TCR-
 
a
 
/
 
b
 
, and –CD8 mAbs (Leu2a), and PE-conjugated– and
PerCP-labeled CD8 mAb were from Becton Dickinson (San Jose,
CA). CD29 (4B4) and PE-conjugated CD45RA mAbs (2H4) were
obtained from Coulter Immunology (Hialeah, FL). FITC-labeled
CD45RO mAb (UCHL1) was purchased from DAKO (Glos-
trup, Denmark). Streptavidin red 670 was obtained from GIBCO
BRL (Gaithersburg, MD).
Biotinylated CLB-IL-4/1 mAb (anti–human IL-4, mouse
IgG1; reference 24) was provided by Dr. T. van der Pouw-Kraan
(CLB) and biotinylated MD-1 mAb (anti–human IFN-
 
g
 
, mouse
IgG1) was obtained from Dr. P. van der Meide (Netherlands Or-
ganisation for Applied Sciences TNO, Rijswijk, The Nether-
lands). Biotinylated anti–human IL-2, FITC-conjugated anti–
human TNF-
 
a
 
, and FITC-conjugated antiperforin mAbs were
purchased from Hölzel Diagnostika (Köln, Germany). Anti-
granzyme B mAb, provided by Dr. C.E. Hack (CLB), was obtained
after immunization of BALB/c mice with native granzyme B.
The following recombinant human cytokines were used: IL-4
and IFN-
 
g
 
 (Genzyme Corp., Cambridge, MA), IL-15 (Pepro-
Tech, London, UK), IL-2 (gift of Sandoz, Vienna, Austria), IL-6
(provided by Professor L. Aarden, CLB), IL-10 (gift of Dr. J. de
 
Vries, DNAX, Palo Alto, CA), and IL-12 (donated by Dr. S.
Wolf, Genetic Institute, Cambridge, MA).
 
Cell Preparation and Flow Cytometry.
 
Human PBMCs were
isolated from buffy coats of healthy donors by Ficoll-Paque den-
sity centrifugation (Pharmacia Biotech AB, Uppsala, Sweden).
For phenotypic analysis (Table 1), CD8
 
1
 
 cells (
 
.
 
95% CD8
 
1
 
CD3
 
1
 
TCR-
 
a
 
/
 
b
 
1
 
CD16
 
2
 
) were purified by incubating PBMCs
with saturating amounts of CD4, CD19, CD16, and CD14 mAbs
followed by depletion of positive cells with Dynal beads (Dynal,
Oslo, Norway) as previously described (18). Triple color immuno-
fluorescence analysis was performed as previously described (23).
In brief, purified CD8
 
1
 
 T cells were incubated with an unlabeled
mAb followed by FITC-conjugated goat anti–mouse Ig staining.
After blocking free binding sites on the goat anti–mouse conju-
gate with 10% normal mouse serum, cells were incubated with
PE-conjugated CD45RA and biotinylated CD27 mAbs. The lat-
ter was then stained with Streptavidin red 670.
For subset purification, CD8
 
1
 
 T cells were prepared by posi-
tive enrichment using the MACS system (Miltenyi Biotec, Ber-
gisch-Gladbach, Germany). In brief, PBMCs (10
 
7
 
 cells/80 
 
m
 
l in-
cubation buffer; PBS/2% FCS/5 mM EDTA) were stained with
CD8 microbeads (Miltenyi Biotec; 20 
 
m
 
l/10
 
7
 
 positive cells) for
15 min at 8
 
8
 
C. After one washing, step cells were resuspended in
incubation buffer (10
 
7
 
 cells/400 
 
m
 
l) and enrichment was per-
formed with BS columns (capacity: 10
 
8
 
 cells) and the VarioMACS
magnet according to manufacturer’s instructions. The resulting
CD8
 
1
 
 T cells were 
 
.
 
98% CD8
 
1
 
CD3
 
1
 
TCR-
 
a
 
/
 
b
 
1
 
CD16
 
2
 
 as de-
termined by immunofluorescence analysis with directly labeled mAb.
Next, cells were stained with PE-conjugated CD45RA and FITC-
conjugated CD27 and sorted into CD45RA
 
1
 
CD27
 
1
 
, CD45RA
 
1
 
CD27
 
2
 
, and CD45RA
 
2
 
CD27
 
1
 
 populations (purity: 
 
.
 
98%) on a
FACStar
 
Ò
 
.
 
Detection of Fas-ligand mRNA.
 
Total RNA was prepared (TRI-
zol Reagent; Life Technologies, Paisley, UK) from 2.5 
 
3
 
 10
 
6
 
 sorted
T cell subsets (see above). Single-stranded cDNA was synthesized
from RNA in a 20-
 
m
 
l reaction mixture containing 500 ng
oligo(dT)
 
12–18
 
 and 200 U reverse transcriptase (RT).
 
1
 
 1 
 
m
 
l of the
reaction mixture was diluted with 11.5 
 
m
 
l of PCR buffer con-
taining 2 mM MgCl
 
2
 
 and 100 pmol of forward and reverse oligo-
nucleotides. Two PCR reactions were set up for each cDNA,
corresponding to Fas ligand (forward: 5
 
9
 
-GGGTCGACGGGA-
TGTTTCAGCTCTTCCACCTAC -3
 
9
 
;  reverse: 5
 
9
 
-GCTCTA-
GAACATTCCTCGGTGCCTGTAAC-3
 
9
 
; reference 25) and
HPRT (hypoxanthine-guanine phosphoribosyltransferase; for-
ward: 5
 
9
 
-TATGGACAGGACTGAACGTCTTGC-3
 
9
 
; reverse:
5
 
9
 
-GACACAAACATGATTCAAATCCCTGA-3
 
9
 
; reference 26).
PCR products were resolved on a 1% agarose gel containing ethid-
ium bromide.
 
Flow Cytometric Detection of Cytokine Production and Intracellular
Staining for Perforin and Granzyme B.
 
Flow cytometric measure-
ment of cytokine production was performed as previously de-
scribed (27, 28). In brief, 10
 
6
 
 cells/ml were stimulated for 4 h (IL-4,
IFN-
 
g
 
, and TNF-
 
a
 
) or 8 h (IL-2) with 1 ng/ml PMA and 1 
 
m
 
M
ionomycin in the presence of the protein-secretion inhibitor
monensin (1 
 
m
 
M; all from Sigma Chemical Co., St. Louis, MO).
This short-term stimulation did not alter the membrane pheno-
type with respect to CD45 or CD27 expression. After cell surface
staining with PE-conjugated CD45RA and FITC-conjugated
 
1
 
Abbreviations used in this paper:
 
 B-LCL, B lymphoblastoid cell lines; p,
precursors; RT, reverse transcriptase. 
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CD27 cells were washed twice with cold PBS and fixated with
PBS/4% paraformaldehyde (at 4
 
8
 
C for 5 min). Fixation was fol-
lowed by permeabilization with PBS/0.1% saponin (Sigma
Chemical Co.)/10% human pooled serum (at 4
 
8
 
C for 10 min).
For all subsequent incubation and washing steps, PBS/0.1% sapo-
nin/0.5% BSA was used. Staining of the cytoplasm with biotiny-
lated cytokine mAbs (IL-2, IL-4, and IFN-
 
g
 
; all 5 
 
m
 
g/ml) was
followed by incubation with Streptavidin red 670 (both at 4
 
8
 
C
for 20 min). Biotinylated or FITC-conjugated mouse IgG1 con-
trol mAbs (DAKO) were used as negative controls. Data acquisi-
tion was performed on a FACScan
 
Ò
 
 and analysis was done using
PC-Lysis software.
Intracellular content of perforin and granzyme B was measured
in freshly isolated CD8
 
1
 
 cells without previous stimulation. A
permeabilization and staining protocol identical to that described
above for the cytokine analysis was used.
 
Cell Culture and Activation.
 
All cell culture experiments were
performed in IMDM supplemented with 10% FCS and antibiot-
ics. Sorted CD8
 
1
 
 T cell subsets (5 
 
3
 
 10
 
4
 
 cells/well) were stimu-
lated with a combination of three CD2 mAbs (CLB-T11.1/1,
CLB-T11.2/1, and CLB-HIK27, all 5 
 
m
 
g/ml) in the presence or
absence of the following recombinant human cytokines: IL-2 (50
U/ml), IL-4 (10 ng/ml), IL-6 (100 U/ml), IL-10 (100 U/ml), IL-12
(1 ng/ml), IL-15 (10 ng/ml), and IFN-g (100 U/ml). Proliferation
was measured on day 4 by adding 0.2 mCi/well of [3H]thymidine
(Amersham, Buckinghamshire, UK) during the last 4 h of culture.
All cultures were set up in triplicate.
To measure cytokine secretion, triplicate cultures of sorted cells
(2.5 3 104) were stimulated with PMA (100 ng/ml) and ionomy-
cin (1 mM). Supernatant was taken after 24 h for detection of IL-2
and on day 4 for measurement of IFN-g, TNF-a, and IL-4 con-
tent. In our experience, the indicated time points have been
proven optimal. IFN-g, TNF-a, and IL-4 were detected with
specific ELISAs (CLB). IL-2 production was measured in a bioas-
say using IL-2–dependent mouse CTLL cells (29).
Cytotoxicity Assay. CTL activity was determined in a CD3
mAb–mediated cytotoxicity assay as previously described (30). In
brief, FcR-bearing P815 target cells were radiolabeled with
Na51CrO4 (Amersham) for 30 min at 378C. Purified CD81 T cell
subsets were incubated with P815 target cells at varying effector/
target ratios in the presence or absence of 5 mg/ml CD3 mAb
(CLB-CD3/4.1). After a 4 h incubation period at 378C, the su-
pernatants of triplicate cultures were collected and counted in a
gamma counter. Specific cytotoxicity was determined according
to the formula: percentage of specific lysis 5 100 3 [(cpm exper-
imental release 2 cpm spontaneous release)/(cpm maximal re-
lease 2 cpm spontaneous release)]. The standard error of the
mean percentage lysis did not exceed 5%.
Determination of HIV-1–derived Peptide-specific CTL Precursor Fre-
quency. HIV-1–specific CTL precursors (CTLp) were expanded
in vitro by Ag-specific stimulation and frequencies of RT derived
peptide aa 244-252 (IVLPEKDSW)–specific CTLp were deter-
mined as previously described (31, 32). In brief, cryopreserved
PBMCs from an HIV-1 seropositive individual (L090; for case
report see reference 32) were thawed and sorted into CD81
CD45RA1CD271 and CD81CD45RA2CD271 subsets. Sorted
cells were cocultivated with stimulator cells (paraformaldehyde
fixated autologous EBV-transformed B lymphoblastoid cell lines
[B-LCL] infected with five multiplicity of infection of recombi-
nant vaccinia virus expressing HIV-1Lai RT) and irradiated feeder
cells (autologous PBMCs; references 31, 32). At days 2 and 9, mi-
crocultures were fed with rIL-2 (10 U/ml Proleukin; provided by
Table 1. Phenotypic Characterization of CD81 T Cell Subsets*
CD45RA1CD271 CD45RA1CD272 CD45RA2CD271 CD45RA2CD272
Homing receptors
CD62L 76 6 9‡ 28 6 13i 20 6 7i 30 6 3i
Integrins
CD49d 25 6 13 87 6 2i 41 6 15i 34 6 20
CD49e 25 6 14 76 6 12i 56 6 6i 61 6 12i
CD29 27 6 15 93 6 2i 73 6 6i 83 6 3i
CD11a 290 6 60§ 716 6 50i 369 6 100 317 6 100
CD18bright 21 6 20 87 6 7i 47 6 17 32 6 18
CD11b 10 6 7 67 6 13i 9 6 3 25 6 3i
Activation and costimulatory molecules
CD58 18 6 16 86 6 8i 80 6 8i 88 6 10i
CD28 77 6 12 17 6 4i 83 6 2 50 6 7i
CD57 1.0 6 0.7 50 6 13i 10 6 6i 14 6 9i
CD95 10 6 1§ 29 6 8i 56 6 2i 58 6 10i
*CD81 cells were .97% CD31TCR-a/b1CD162 in all subsets.
‡Percentage of positive cells 6 SD, n 5 5.
§Mean fluorescence intensity 6 SD, n 5 5.
iSignificant difference (P ,0.05) compared to the CD45RA1CD271 subset (Wilcoxon signed rank test).1410 Human CD81 T Cell Subsets
Dr. R. Rombouts, Chiron Benelux B.V., Amsterdam, The Neth-
erlands). Cultures were restimulated at day 7 by addition of fixated
autologous stimulator cells in the presence of rIL-2 (10 U/ml). On
day 15, wells were split and tested for cytotoxicity on 51Cr-labeled
autologous B-LCL that were preincubated for 30 min at room
temperature with synthetic peptide at a final concentration of 5 mg/
ml. Lysis of target cells was measured as described above. Wells
were considered positive when 51Cr-release exceeded 10% of
specific lysis. Frequency estimates were made using the “single-
hit Poisson model” described by Strijbosch et al. (33).
Helper and Suppressor Activity for Ig Production. CD81 T cells
and CD81 subsets were prepared as described above. The CD82
fraction obtained after purification of CD81 cells was either de-
pleted of monocytes, NK cells, the remaining CD81 T cells, and
B cells with CD14, CD16, CD8, and CD19 mAbs and magnetic
beads (Dynal) to generate CD41 T cells (.95% CD41) or else
depleted of monocytes, NK cells, and T cells with CD14, CD16,
and CD3 mAbs to prepare B cells (.90% CD191). To determine
helper capacity, cells of the different T cell subsets (5 3 104/well)
were cultured with autologous B cells (5 3 104/well) in 96-well
flat-bottomed microtiter plates (Greiner, Nürnberg, Germany)
coated with 5 mg/ml CD3 mAb (CLB-CD3/3). Suppressor ac-
tivity was determined by adding cells of the different CD81 T cell
subsets (5 3 104/well) to a coculture of autologous CD41 T and
B cells. All cultures were set up in triplicate and supernatants were
harvested after 14 d and tested for Ig content. IgM and IgG pro-
duction was measured by ELISA.
Results
Phenotypic Heterogeneity of the CD81 T Cell Subset. As has
been previously noted (21), in contrast to CD41CD272 T
lymphocytes, which are exclusively CD45RA2, within the
circulating CD81 compartment CD272 T cells can be
found within both CD45RA2 and CD45RA1 fractions
(Fig. 1). These CD81CD45RA1CD272 cells are, like CD81
CD45RA2CD45R01 cells, absent from cord blood (Fig. 1).
Therefore, we hypothesize that in response to antigen two
separate primed CD81 populations may develop in humans:
(a) a population of CD45RA2 T cells, and (b) a population
of CD45RA1CD272 T cells. This study was performed to
analyze whether these phenotypes discriminate between
functionally distinct CD81 subsets.
In a population of healthy adult donors (n 5 30), the dis-
tribution of the CD81 T cell subsets defined by simulta-
neous CD45RA and CD27 staining was as follows (for def-
inition of the subsets see Fig. 1): (1) CD45RA1CD271
cells 55 6 17% (range 28–83%); (2) CD45RA2CD271
cells 25 6 11% (range 9–48%); (3) CD45RA1CD272 cells
13 6 13% (range 1–50%); and (4) CD45RA2CD272 cells
4 6 3% (range 0–15%).
To further define the cell surface phenotype of these
subsets, CD81 T cells were purified from peripheral blood
and analyzed in triple color immunofluorescence. As ex-
pected on the basis of the observation that these were the
only cells present in cord blood, CD45RA1CD271 cells
showed characteristics of unprimed cells since they were
CD62L1 and had low CD49d, CD49e, CD29, CD11a/
CD18, and CD58 expression. The majority of cells were
CD281 and did not express CD45R0 (Table 1 and data
not shown). The CD45RA2 population had features of an-
tigen-primed cells. CD62L was downregulated, and CD49e,
CD29, and CD58 were upregulated when compared to the
Figure 1. Triple color immunofluorescence analysis of cord blood
lymphocytes and PBMCs from an adult donor. Cells were simultaneously
stained with either CD4-PerCP or PerCP-labeled CD8 in combination
with PE-conjugated CD45RA and FITC-conjugated CD27 mAbs. Cells
were gated on forward scatter/side scatter and PerCP-fluorescence. Four
distinct populations can be defined within CD81 cells from adult blood:
(1) CD45RA1CD271 cells, (2) CD45RA2CD271 cells, (3) CD45RA1
CD272 cells, and (4) CD45RA2CD272 cells. Note that there is also a
transitional population with dull CD45RA expression. As in the CD41
subset (23), these cells have an intermediate phenotype for the studied surface
markers (data not shown). Functionally, this subset was not analyzed.
Figure 2. (A) CD81 T cell
subsets differ in Fas expression.
(B) Fas ligand (FasL) and HPRT
(hypoxanthine-guanine phospho-
ribosyltransferase)  mRNA expres-
sion in sorted CD81 T cell
subsets as assessed by RT-PCR.
Lane  A, CD8 total; lane B,
CD81  CD45RA1CD271; lane C,
CD81  CD45RA1CD272; lane
D, CD81 CD45RA2CD271.1411 Hamann et al.
unprimed population. The main difference between CD271
and CD272 cells within the CD45RA2 population was the
expression of CD28. Although the majority of CD271 cells
expressed the antigen, only half of the CD272 cells were
CD281.
Although CD45R0 was absent from CD45RA1CD272
cells, these T cells had a number of features compatible with
a primed phenotype. CD62L was found to be downregu-
lated, whereas CD49d, CD49e, CD29, CD11a/CD18,
and CD58 were highly expressed. In comparison to the
CD45RA2 population, expression levels of CD49d and
CD11a/CD18 were even higher on CD45RA1CD272
cells. Remarkably, CD11b and CD57 were present on
.50% of the cells and the majority did not express CD28.
Fas (CD95) was not expressed on CD81CD45RA1
CD271 lymphocytes but could be detected on the majority
of CD45RA1CD272 T cells. It should be noted that the
antigen density on the latter population was markedly
lower than on CD81CD45RA2 T cells (Table 1 and Fig. 2
A). Interestingly, Fas ligand mRNA was not present in
CD81CD45RA1CD271 T cells but was strongly ex-
pressed in CD81CD45RA1CD272 lymphocytes (Fig. 2 B,
lanes B and C). In contrast, only trace amounts of Fas ligand
mRNA were detected in CD81CD45RA2CD271 cells
(Fig. 2 B, lane D).
Finally, it should be noted that a CD81CD271 popula-
tion expressing low levels of CD45RA can be found in
most donors (Fig. 1). Analogous to similar cells within
the CD41 T cell compartment (34), these cells coexpress
CD45R0 and were found to have an intermediate mem-
brane phenotype between CD45RA1CD271 and CD45RA2
CD271 T cells (data not shown).
Cytokine Production Capacity of CD81 T Cell Subsets.
In contrast to naive T cells, which primarily secrete IL-2,
the ability to produce a variety of cytokines is a typical fea-
ture of primed T cells (35). Cytokine production capacity
of CD81 T cell subsets was measured after stimulation for 4 h
with PMA and ionomycin at a single cell level (Fig. 3 and
Table 2). CD81CD45RA1CD271 cells paralleled naive
CD41 cells in that IL-2 was the main cytokine produced
by this subset. In agreement with what would be expected
from primed cells, CD81CD45RA2 cells were able to se-
crete IL-2, IL-4, IFN-g, and TNF-a. IL-41 cells were ex-
clusively found within this population with both CD271
and CD272 cells contributing to the total IL-4 secretion.
Also with respect to cytokine expression, the CD45RA1
CD272 subset showed characteristics of antigen-experienced
cells, in that a high percentage of IFN-g and TNF-a
producers could be detected. Remarkably, in contrast to
CD45RA2 cells, neither IL-2 nor IL-4 production was
found. Since IL-2 production in CD45RA1 cells has been
described to reach its maximum later than in CD45RA2
cells (36), we also analyzed 8-h stimulated cells. Indeed, the
frequency of IL-2 producers increased in the CD45RA1
CD271 subset. However, also at this time point, CD45RA1
CD272 cells did not produce any IL-2. From Fig. 3 it should
be noted that, with respect to the cytokine secretion pat-
tern, cells with a CD27dull expression behave as CD272 T
cells in this assay. Furthermore, expression of surface mark-
ers on these cells was also comparable to CD272 cells (data
not shown).
The results obtained by intracellular cytokine staining
were confirmed by measuring the cytokine content of the
Figure 3. Intracellular measurement of cytokines in CD81 T cells. Pu-
rified CD81 cells were stimulated for 4 h (IFN-g and IL-4) or 8 h (IL-2)
with PMA and ionomycin in the presence of the protein secretion inhib-
itor monensin. After surface staining with CD45 and CD27 mAbs, cells
were fixated and permeabilized and intracellular accumulated cytokines
were detected with specific mAbs. The histograms show the cytokine
staining. Dotted lines indicate the negative controls; the positive cell frac-
tion is painted black; and the dot-plots show the distribution of positive
cells (black) among the total cell population (gray).
Table 2. Intracellular Measurement of Cytokine Production in 
CD81 T Cell Subsets
Cells IL-2* IL-2‡ IFN-g* TNF-a* IL-4*
Total CD81 17 6 2 16 51 6 15 48 6 14 3 6 1
CD45RA1CD271 9 6 42 76  6  2 12 6 4 ,1
CD45RA1CD272 1 6 1 ,1 77 6 16 69 6 10 ,1
CD45RA2CD271 43 6 17 31 76 6 9 78 6 86  6  4
CD45RA2CD272 33 6 14 16 76 6 12 69 6 69  6  8
*Cells were stimulated for 4 h, mean percentage of positive cells 6 SD,
n 5 6.
‡Cells were stimulated for 8 h, mean percentage of positive cells, n 5 2.
Table 3. Cytokine Secretion by CD81 T Cell Subsets
Cells* IL-2 IFN-g TNF-a IL-4
U/ml pg/ml pg/ml pg/ml
CD45RA1CD271 100 2,860 370 ,1
CD45RA1CD272 ,10 9,310 2,220 ,1
CD45RA2CD271 100 11,940 1,660 10
*Sorted cells (2.5 3 104) were stimulated with PMA (100 ng/ml) and
ionomycin (1 mM) for 4 d. Cytokine content of the supernatants was
tested with a bioassay for IL-2 and ELISAs for IFN-g, TNF-a, and IL-4.1412 Human CD81 T Cell Subsets
supernatant after 4 d of culture in the presence of PMA and
ionomycin (Table 3). Again, CD45RA1CD271 T cells
mainly produced IL-2. CD45RA2 cells secreted all mea-
sured cytokines, whereas CD45RA1CD272 cells were only
capable of IFN-g and TNF-a production.
To test if the distinction in cytokine production profiles
between the two primed CD81 T cell subpopulations was
reflected in their proliferation capacities, three fractions were
sorted from purified CD81 T cells, i.e., CD45RA1CD271,
CD45RA1CD272, and CD45RA2CD271 cells, and stim-
ulated with a combination of CD2 mAbs supplemented with
various cytokines (Fig. 4). The CD45RA2CD272 popula-
tion could not be analyzed because of the low number of
these cells in most donors (see above). Culture of the sorted
cells with the indicated cytokines alone did not result in
proliferation (data not shown). In accordance with a previous
report (18) on stringent activation requirements of unprimed
CD81 T cells, CD45RA1CD271 cells were not able to
proliferate in response to CD2 mAbs alone, but addition of
IL-2, -15, -4, and, to a lesser extent, -12 resulted in a vig-
orous proliferative response, whereas IL-6 and -10 and
IFN-g had no effect on proliferation. In contrast, CD2
mAbs alone were sufficient to induce proliferation of
CD45RA2CD271 cells. IL-2, -15, and -12 further in-
creased proliferation, but IL-4, -6, and -10, and IFN-g
only marginally influenced the CD2-induced response.
Proliferation of CD45RA1CD272 cells was only observed
in the presence of either IL-2 or -15. However, the magni-
tude of the response was lower than that of the other two
populations.
CD45RA1CD272, but not CD45RA2CD271 T Cells,
Have Cytolytic Activity without Previous In Vitro Stimula-
tion. Our data thus far have shown that CD45RA1
CD272 cells possess a number of phenotypic characteristics
that have been associated with murine (9) and human (11,
15, 16, 37) cytolytic T cells and that these cells secrete
IFN-g and TNF-a, two lymphokines known to play a role
in controlling virus infections (38). Therefore, we addressed
the question of whether these cells behave as CTLs ex vivo.
Purified CD81 cells were sorted into the distinct subsets and
their cytotoxic capacity was tested in a CD3 mAb–mediated
redirected cytotoxicity assay (Fig. 5). As expected,
unprimed CD45RA1CD271 cells were not able to lyse the
target cells. CD45RA2CD271 cells had a low but detectable
cytolytic activity at relatively high effector/target ratios.
Strikingly, however, the CD45RA1CD272 population
had potent cytolytic activity.
Fas–Fas ligand interaction is an important mechanism
used by CTLs for cell-mediated cytotoxicity (39, 40). Next
to this, CTL effectors can kill target cells by releasing a pore-
forming protein (perforin) and serine proteases (granzymes),
which are stored in intracellular granules, into the vicinity
of target cell membranes (41, 42). We analyzed freshly iso-
Figure 4. Proliferative capacity of CD81 T cell subsets. Purified CD81
T cells were sorted into the indicated subsets and stimulated with a com-
bination of three CD2 mAbs in the presence of different cytokines. Pro-
liferation was measured on day 4 by adding [3H]thymidine during the last
4 h of the culture. Results from one out of three experiments are shown.
Figure 5. Cytotoxic capaci-
ties of CD81 T cell subsets. Puri-
fied CD81 T cells were sorted
into the indicated subsets and cy-
totoxicity was directly analyzed
against P815 target cells in the
presence of CD3 mAb in a 4-h
51Cr-release assay. All effector
populations used were unable to
lyse P815 cells in the absence of
CD3 mAb (lysis ,3%), thus ex-
cluding NK cell–like activity in
this system (data not shown).
Results are the mean 6 SD of
three independent experiments.
The distribution of cells in the
different subsets was as follows:
CD45RA1CD271, 18–37%; CD45RA1 CD272, 7–23%; and CD45RA2
CD271, 30–38%. (CD81 T cells, squares; CD81CD45RA1CD271, trian-
gles; CD81CD45RA2CD271; plus; CD81 CD45RA1CD272, circles.)
Figure 6. Expression of mediators of cytotoxicity in CD81 T cell sub-
sets. After surface staining of freshly isolated CD81 cells with CD45RA
and CD27 mAbs, cells were fixated and permeabilized and intracellularly
present perforin and granzyme B were detected with specific mAbs. The
histograms show the staining for the intracellular proteins. Dotted lines
indicate the negative controls. The positive cell fraction is painted black.
The dot-plots show the distribution of positive cells (black) among the to-
tal cell population (gray). Note that the different dot-plot staining is due
to the use of either biotinylated CD27 mAb in combination with red 670
or FITC-labeled CD27 mAb.1413 Hamann et al.
lated CD81 cells for the presence of perforin and granzyme
B. In accordance with the cytolytic capacities of the dif-
ferent subsets, nearly all cells of the CD45RA1CD272
population contained perforin and granzyme B. Unprimed
CD45RA1CD271 cells did not contain these enzymes,
whereas low staining could be found within the CD45RA2
population (Fig. 6 and Table 4). As already seen in the
analysis of cytokine production, cells with dull CD27 ex-
pression showed a similar granzyme B and perforin expres-
sion pattern to CD272 cells.
The CD45RA2CD271 Subset Contains Antigen-specific
Precursor CTL. CTL effectors exert direct ex vivo cy-
tolytic activity, whereas memory cells need restimulation with
antigen to acquire cytotoxic function. Since CD45RA2
CD271 cells, which resemble memory T cells with respect to
membrane phenotype and cytokine secretion ability, showed
no direct ex vivo cytolytic activity, we studied whether cy-
totoxic effectors could be generated from this population.
To this purpose, PBMCs from an HIV-1 seropositive indi-
vidual were sorted into CD81CD45RA1CD271 and CD81
CD45RA2CD271 subsets. CTLs from this individual had
been previously found to recognize an HLA-B57 restricted
epitope of the HIV-1LAI RT aa 244-252 (Klein, M.R.,
unpublished results). Neither CD45RA1CD271 nor
CD45RA2  CD271 cells showed direct ex vivo cytotoxic-
ity as measured in a redirected kill assay as described above.
To determine the frequency of peptide-specific CTLp within
the distinct subsets, sorted cells were seeded in serial dilu-
tions and stimulated with autologous B-LCL infected with
recombinant vaccinia virus expressing the HIV-1LAI RT gene.
On day 15, effector cells were tested for cytotoxicity on
autologous B-LCL pulsed with the HIV-1LAI reverse tran-
scriptase–derived peptide aa 244-252 (Fig. 7). Indeed, cyto-
toxic effector cells could be generated from the CD45RA2
CD271 subset, which had an enhanced frequency of pep-
tide-specific CTLps (61/106 cells) as compared to the
CD45RA1CD271 subset (15/106 cells).
CD45RA2CD271 but not CD45RA1CD272 Support Ig
Secretion In Vitro. Apart from their cytolytic capacities,
CD81 cells have been shown to exert suppressor activity as
well as helper activity for Ig synthesis (43). Helper capacity
of CD81 T cell subsets was tested in a CD3 mAb–driven T
cell–dependent B cell differentiation assay (44). When total
CD41 and CD81 cells were compared, helper activity was
preferentially found in the CD41 fraction (Fig. 8 A). How-
ever, when CD81 cells were further separated into the in-
dicated subsets, it was found that the CD45RA2CD271
cells were also able to support B cell differentiation, whereas
both the CD45RA1CD271 and the CD45RA1CD272 cells
showed no helper activity.
To test suppressor capacity, sorted CD81 subsets were
added to the autologous coculture of CD41 and B cells
(Fig. 8 B). In accordance with a previous study (43), total
CD81 T cells markedly reduced IgM and IgG synthesis in
this system. When the CD81 cells were further separated
into the different subsets, suppressor activity was primarily
found in the CD45RA1CD271 fraction. This effect was not
due to enhanced IL-4 consumption of CD81CD45RA1
CD271 cells, as addition of exogenous IL-4 did not over-
come suppression of the Ig synthesis.
In summary, within the CD81 compartment, helper and
suppressor activity could be ascribed to CD45RA2CD271
and CD45RA1CD271 T cells, respectively, whereas the
CD45RA1CD272 does not appear to directly influence B
cell differentiation.
Discussion
In this study, we define discrete subsets (summarized in
Table 5) within the CD81 T cell population based on ex-
Table 4. Expression of Cytotoxic Mediators by CD81 
T Cell Subsets
Cells Perforin Granzyme B
Total CD81 24 6 7* 27 6 13
CD45RA1CD271 ,13   6  1
CD45RA1CD272 91 6 6 89 6 9
CD45RA2CD271 16 6 11 16 6 6
CD45RA2CD272 54 6 16 36 6 32
*Percentage of positive cells 6 SD (n 5 4).
Figure 7. Using standard lim-
iting dilution analysis, the CTLp
frequencies for the HIV-1LAI
RT-derived peptide aa 244-252
(IVLPEKDSW) were quantified
in CD81 T cell subsets from an
HIV-infected individual. Pep-
tide-specific CTLp frequencies
were calculated by subtracting
CTLp frequencies determined
with targets without peptide
from CTLp frequencies deter-
mined with targets pulsed with 5
mg/ml of RTLAI peptide aa 244-
252. Mean 1 SD of three sepa-
rate experiments.
Figure 8. Helper and suppressor capacities of CD81 T cell subsets. B
cells were cocultured with the indicated T cell subsets in CD3-coated wells
for 14 d. Ig content of the supernatant was measured with specific ELI-
SAs. (A) Cells of the different T cell populations were cultured with B
cells alone to determine their helper capacities. (B) Cells of the distinct
CD81 subsets were added to the coculture of autologous B and CD41 T
cells to measure their suppressor activity. One out of two comparable ex-
periments is shown. The distribution of cells in the different subsets was as
follows: CD45RA1CD271, 50%; CD45RA1CD272, 5%; and CD45RA2
CD271, 35%.1414 Human CD81 T Cell Subsets
pression patterns of CD45RA and CD27. First, similar to
the CD41 T cell subpopulation, CD45RA1CD271 T cells
are the only CD81 lymphocytes present in cord blood, and
the analysis of phenotype and function showed that this
population primarily contains unprimed (naive) cells.
CD81CD45RA2CD271 lymphocytes are T cells that have
several features of antigen-experienced cells. In comparison
to phenotypic data obtained in the murine system, these
CD81 cells most closely resemble memory-type cells, as
they express intermediate levels of CD11a/CD18 and
CD49d, but have no membrane expression of CD11b (9).
Indeed, this CD81CD45RA2CD271 population from an
HIV-1–infected individual contained, compared to CD81
CD45RA1CD271 T cells, an enhanced frequency of CTLp
specific for an HIV-1 RT-derived peptide. In line with
this, a study by Merkenschlager and Beverley (17) docu-
mented an elevated precursor frequency to recall antigens
within the CD81CD45RA2CD45R01 fraction. A second
population that has features of past antigen stimulation has a
CD81CD45RA1CD272 phenotype. Not only with re-
spect to cytolytic potential, but also regarding surface ex-
pression of high levels of CD11b and CD49d and absence
of the lymph node homing receptor CD62L, these cells
fulfill the criteria of CTL effector-type cells that have been
defined in murine models. Further characterization of the
CD81CD45RA1CD272 population allowed us to deter-
mine the functional abilities of human CTL-type effector
cells as they occur in vivo. The data show that (a) on a per
cell basis the vast majority of effector cells are able to pro-
duce both IFN-g and TNF-a, (b) these cells contain high
amounts of perforin and granzyme B, (c) Fas ligand mRNA
is abundantly expressed in freshly isolated effector cells, and
(d), that these cells exert potent cytotoxic activity without
previous in vitro stimulation. Finally, a fourth population
constituted of CD45RA2CD272 T cells can be found in
the CD81 fraction of all donors. The frequency of these
cells in healthy donors is very low (usually ,4%) and there-
fore not accessible for assays that depend on vast quantities
of purified cells. However, based on membrane phenotype,
cytokine production pattern, and expression of perforin
and granzyme B, it is suggested that this population may
contain both memory- and effector-type cells.
Based on the finding that the majority of CD81CD45RA1
CD272 T cells lack CD28 expression, it was not surprising
to find that this subset shares a number of features that have
been previously reported for CD282 lymphocytes (15, 45,
46). Azuma et al. (15) showed that CD81CD282 T cells
are able to lyse FcR-bearing targets cells in the presence of
CD3 mAb. Moreover, Berthou et al. recently reported that
most of the perforin containing CD81 lymphocytes lack
the CD28 molecule (47). The current data confirm and ex-
tend these observations by showing that not only perforin
but also granzyme B and Fas ligand are expressed within
this T cell subset, which is likely to contribute to the lysis
of target cells (39, 40). It is of interest to note that two ma-
jor costimulatory receptors for T cell growth and cytokine
production, CD28 and CD27, are absent from this effec-
tor-type T cell. The absence of CD28 implies that this cell
type is unable to interact productively (in terms of induc-
tion of clonal expansion) with professional antigen-present-
ing cells. This inability is underscored by the observation
that, in marked contrast to both the CD45RA1CD271 and
CD45RA2CD271 subsets, CD45RA1CD272 T cells do
not proliferate in response to IL-12, one of the major T cell
stimulatory cytokines secreted by activated antigen-pre-
senting cells (48). Finally, absence of CD27 on these cells also
precludes costimulatory interactions with other, activated
lymphocytes (49). Analysis of the proliferation requirements
showed that CD45RA1CD272 T cells responded poorly
to most stimuli, which is in agreement with functional
studies on the CD81CD282 T cell subset (15, 46). How-
ever, CD45RA1CD272 T cells do respond to IL-2 and to
a lesser extent to IL-15, which suggests that in vivo this
subset might be influenced by Th-derived signals.
In mice, the expression of CD49d nicely separates naive
(low), memory (intermediate), and effector (high expres-
sion) T cells, and a study by Christensen et al. has shown
that CD49d plays a critical role in efficient homing of ef-
fector T cells during virus infections (13). Also, in humans
CD49d expression correlates well with the distinct CD81
subsets, CD45RA1CD272 T cells being the ones with the
highest expression. Apart from CD49d, a b1 integrin inter-
acting with vascular cellular adhesion molecule–1 on acti-
vated endothelium and also the high expression of the b2
integrins CD11a and CD11b (Table 1) will probably influ-
Table 5. Properties of CD81 T Cell Subsets
Naive Memory Effector
Genes expressed
CD45RA 12 1
CD27 11 2
CD28 11 2
CD11a 611 1
CD11b 221 1
CD49d 211 1
CD57 221 1
CD95 21 1 1
Fas ligand 261 1
IL-2 11 1 2
IL-4 21 2
IFN-g 2 11 11
TNF-a 2 11 11
Perforin 261 1
Granzyme B 261 1
Functions
Cytoxicity 261 1
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ence the homing properties of these effector-type cells,
which may be different from those of naive or memory
cells. Indeed, CD81CD45RA1CD272 cells were conspic-
uously absent from tonsils, whereas CD45RA2CD271 cells
could readily be demonstrated in this lymphoid tissue (Ha-
mann, D., unpublished data). In line with this observation,
it was reported that CD11b1 cells are present in blood,
liver, and spleen, but absent from tonsil, lymph node, and
thymus (45).
Thus, it would seem that in response to antigen, two
types of primed CD81 populations may develop. First, an
effector-type population with high levels of granzyme, per-
forin, and Fas ligand expression that exerts cytolytic activ-
ity, which has lost the ability for autocrine proliferation but
has retained the ability to synthesize IFN-g and TNF-a,
two cytokines implicated in the neutralization of viruses.
Second, a population of memory-type cells, which is not
cytolytic without further activation, produces a wide range
of cytokines and is able to provide helper activity for B cell
differentiation. Kinetic studies in mice showed that effector
T cells can be found relatively early after virus infection (8
d), and decline thereafter. In contrast, memory cells be-
come prominent at a later point (.50 d), and it has been
suggested that effector cells seed the memory pool (9, 50).
However, the relation between these subpopulations in
humans is unclear at this moment. In major contrast to data
obtained in the mouse system, effector-type T cell numbers
in humans are relatively stable over time (.18 months,
Rep, M.H.G., unpublished data). In addition, it has been
reported that CD81CD45RA1CD11abright, CD11b1, and
CD282 T cells increase with age (45, 51, 52) and, in agree-
ment with this (see Table 5 for phenotypic similarities), we
found a similar relationship between age and the percent-
age of CD81CD45RA1CD272 T cells (Rep, M.H.G., un-
published data). The reason for the discrepancy in the ki-
netics of effector-type T cells between mouse and human is
not clear at this moment but it is possible that persistence of
antigen, cross-reactive epitopes (53), and/or stimulatory
cytokines plays a role (54). It can be imagined that these
factors will more readily influence the maintenance of a
polyclonal effector T cell population in a natural environ-
ment than that of the monoclonal T cell population present
in laboratory animals housed under pathogen-free condi-
tions. It is questionable, based on the in vitro experiments,
whether effector T cells that are present in the human cir-
culation have a sizable clonogenic potential. Still, it can be
envisaged that this type of cell contributes to the inhibition
of pathogen spread early in secondary infection through
immediate lysis of infected cells.
In agreement with recent data on CD28 subsets by Mon-
teiro et al. (55), we found shortened telomers in CD81
CD45RA1CD272 compared to CD81CD45RA1CD271
in some donors (Hamann, D., K.C. Wolthers, S.A. Otto,
P.A. Baars, F.M. Miedema, and R.A.W. van Lier, manu-
script submitted for publication). This finding shows that
transition to the CD45RA1CD272 subset is accompanied
by cellular division. Cell cycle analysis showed that, analo-
gous to the CD41 population (23, 56), the CD81 cells
that are in G2M can only be found in the minute fraction
of CD81CD45RAbrightCD45R0bright cells and not in CD-
45RA1CD45R02CD271 T cells (Baars, P.A., unpublished
data). This finding implicates that CD45RA1CD272 cells
could only develop via a CD45RA1CD45R01 and a subse-
quent CD45RA2CD45R01 stage. However, at this mo-
ment we cannot exclude that the transition from CD271 to
CD272 takes place in compartments, such as solid tissue,
which are not readily available for cell-biological analysis.
Finally, similar to what has been described for CD282 (57)
and CD571 (16, 37) T cells, we found a limited usage of
Vb elements by CD81CD45RA1CD272 cells (Hamann,
D., K.C. Wolthers, S.A. Otto, P.A. Baars, F.M. Miedema,
and R.A.W. van Lier, manuscript submitted for publica-
tion). These findings, combined with the data on telomeric
repeat length, infer that these circulating effector-type cells
in humans are generated through antigen-dependent differ-
entiation and proliferation processes.
Analysis of naive, memory, and CTL effector-type CD81
T cells seems relevant not only in patients with chronic vi-
ral infections such as CMV, hepatitis B, or HIV-1, but also
in patients actively immunized with tumor antigens and af-
ter having received an allotransplantation. Patients infected
with CMV have been shown to have an increased percent-
age of CD571 cells within the CD81 population that con-
tains virus-specific CTLs and can be oligoclonal (16). In
HIV-1 infected individuals, an expanded CD282 popula-
tion within the CD81 T cell subset has been reported (46).
This population has been found to be primarily CD571,
exerts potent cytolytic activity, and expresses perforin (46,
58). Interestingly, in contrast to healthy donors where
CD272 and CD282 cells form highly overlapping subsets,
a large population of CD45RA2CD282 cells that still ex-
press the CD27 antigen emerges during acute and persistent
viral infections (Roos, M.T.L., manuscript submitted for
publication), which may point to a sequential downregula-
tion of costimulatory molecules during postthymic T cell
differentiation.
Based on the data presented in this paper, we conclude
that unidimensional analysis of CD81 T cells, using either
CD45RA, CD27, or CD28 mAbs, underestimates the com-
plexity of this subset in humans. Therefore, we propose
that combined staining with CD27 and CD45RA mAbs
provides a tool not only for distinguishing unprimed
CD45RA1CD271 from primed CD45RA2 cells, but also
for following the dynamics and expansion of a CD45RA1
CD272 cytotoxic effector cell population in CD81 T cells
in different disease states.
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